Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Roger Kitterman
AddedMar 31, 2024
UpdatedMay 31, 2026
Roger Kitterman

Roger Kitterman

Co-Founder, Mass Medical Angels

CrunchbaseLinkedIn

Roger Kitterman's Career

Mass Medical Angels
Mass Medical Angels

Boston, MA, US

Co-Founder
Targanox
Targanox

Boston, MA, US

Board Member· Board
Provasculon
Provasculon

Cambridge, MA, US

Board Member· Board
Daktari Diagnostics
Daktari Diagnostics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Roger Kitterman's Career

Mass Medical Angels
Mass Medical Angels
Investment FirmInvestment Firm1752007Boston, MA, US
Co-Founder

Leadership at Mass Medical Angels

Pushwaz VirkPushwaz VirkCo-Founder
Carl BerkeCarl BerkeCo-Founder
Richard AndersRichard AndersCo-Founder
Penny RossanoPenny RossanoBoard Member
Targanox
Targanox
Series A$5.1M82008Boston, MA, US
Board Member· Board

Leadership at Targanox

Joseph LoscalzoJoseph LoscalzoBoard Member
Geoffrey SmithGeoffrey SmithBoard Member
Avi KometzAvi KometzCEO
Gordon LettsGordon LettsCo-Founder
Kate CarrollKate CarrollCo-Founder

Similar to Targanox

NovatargNovatargDurham, NC, USPharmaceuticalsest. 2009NovatargDurham, NC, US · est. 2009

NovaTarg Therapeutics: A private pharma firm specializing in tissue-targeted drug discovery.

Seed · $3.2M5
AgentixAgentixDana Point, CA, USBiopharmaceuticalsest. 2013AgentixDana Point, CA, US · est. 2013

Agentix, a biopharmaceutical firm, develops health solutions and modulates the ECS for therapeutic targets, based in California.

Public · $808.3k7
KinDex PharmaceuticalsKinDex PharmaceuticalsSeattle, WA, USTherapeuticsest. 2009KinDex PharmaceuticalsSeattle, WA, US · est. 2009

KinDex Pharmaceuticals develops novel therapeutics for metabolic disorder treatment.

Angel · $5.8M10
Tigris PharmaceuticalsTigris PharmaceuticalsBonita Springs, FL, USCancer Treatmentsest. 2005Tigris PharmaceuticalsBonita Springs, FL, US · est. 2005

Tigris Pharmaceuticals: Innovating biopharmaceutical solutions for cancer and other medical needs.

Series C · $32.5M6
Provasculon
Provasculon
Investment FirmInvestment Firm$7.3M62007Cambridge, MA, US
Board Member· Board

Leadership at Provasculon

Rainer FuchsRainer FuchsBoard Member
Vincent SegersVincent SegersFounder
Susan J WardSusan J WardBoard Member
Daktari Diagnostics
Daktari Diagnostics
Acquired$85.6M02008Cambridge, MA, US
Board Member· Board

Leadership at Daktari Diagnostics

Stanley LapidusStanley LapidusBoard Member
David M RubinDavid M RubinBoard Member
Bill RodriguezBill RodriguezFounder
Donald B. HawthorneDonald B. HawthorneBoard Member
Aaron SandoskiAaron SandoskiBoard Member
alexalexBoard Member

Roger Kitterman's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Roger Kitterman

Bob SweeneyBob SweeneyFounder · Global Health Impact FundAdam SharkawyAdam SharkawyCo-Founder · Material ImpactDaniel GoldDaniel GoldFounder · MmrglobalPatrick HeimPatrick HeimBoard Member · PreemptSteve OesterleSteve OesterleBoard Member · Paragon 28Robert MittendorffRobert MittendorffBoard Member · Impel Pharmaceuticals